{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:55:04Z","timestamp":1789916104491,"version":"4.0.1"},"reference-count":38,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.3892\/ijo.2012.1662","type":"journal-article","created":{"date-parts":[[2012,10,15]],"date-time":"2012-10-15T10:33:38Z","timestamp":1350297218000},"page":"2109-2118","source":"Crossref","is-referenced-by-count":41,"title":["Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer"],"prefix":"10.3892","volume":"41","author":[{"given":"FUTOSHI","family":"KAWAMATA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROFUMI","family":"KAMACHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKAHIRO","family":"EINAMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHIGENORI","family":"HOMMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUNENORI","family":"TAHARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAYA","family":"MIYAZAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHINYA","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TOSHIYA","family":"KAMIYAMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROSHI","family":"NISHIHARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKINOBU","family":"TAKETOMI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SATORU","family":"TODO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2012,10,15]]},"reference":[{"key":"key20180107184857_b1-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/SLA.0b013e3181d3d2b2","article-title":"Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma","volume":"251","author":"Ito","year":"2010","journal-title":"Ann Surg"},{"key":"key20180107184857_b2-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2220\/biomedres.30.79","article-title":"Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient\u2019s prognosis and recurrent status of extrahepatic bile duct carcinoma","volume":"30","author":"Ohashi","year":"2009","journal-title":"Biomed Res"},{"key":"key20180107184857_b3-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"key20180107184857_b4-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1409x","DOI":"10.1016\/j.suc.2008.07.012","article-title":"Proximal biliary malignancy","volume":"88","author":"Akoad","year":"2008","journal-title":"Surg Clin North Am"},{"key":"key20180107184857_b5-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1429xi","DOI":"10.1016\/j.suc.2008.07.003","article-title":"Distal biliary malignancy","volume":"88","author":"Veillette","year":"2008","journal-title":"Surg Clin North Am"},{"key":"key20180107184857_b6-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107184857_b7-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"key20180107184857_b8-ijo-41-06-2109","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b9-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20180107184857_b10-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol"},{"key":"key20180107184857_b11-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"key20180107184857_b12-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","article-title":"Co-Expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma","volume":"40","author":"Einama","year":"2011","journal-title":"Pancreas"},{"key":"key20180107184857_b13-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b14-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180107184857_b15-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br J Cancer"},{"key":"key20180107184857_b16-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"key20180107184857_b17-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2003.10.012","article-title":"Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays","volume":"35","author":"Swierczynski","year":"2004","journal-title":"Hum Pathol"},{"key":"key20180107184857_b18-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.22024","article-title":"Mesothelin expression correlates with prolonged patient survival in gastric cancer","volume":"105","author":"Baba","year":"2012","journal-title":"J Surg Oncol"},{"key":"key20180107184857_b19-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","article-title":"Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer","volume":"107","author":"Einama","year":"2012","journal-title":"Br J Cancer"},{"key":"key20180107184857_b20-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1309\/37RTWYAEPABYY410","article-title":"S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct","volume":"127","author":"Zhao","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"key20180107184857_b21-ijo-41-06-2109","volume-title":"TNM Classification of Malignant Tumors","author":"Sobin","year":"2002","edition":"6th edition"},{"key":"key20180107184857_b22-ijo-41-06-2109","first-page":"1375","article-title":"Secretion of N-ERC\/mesothelin and expression of C-ERC\/mesothelin in human pancreatic ductal carcinoma","volume":"20","author":"Inami","year":"2008","journal-title":"Oncol Rep"},{"key":"key20180107184857_b23-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","article-title":"Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma","volume":"103","author":"Shimizu","year":"2012","journal-title":"Cancer Sci"},{"key":"key20180107184857_b24-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"key20180107184857_b25-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol Cancer"},{"key":"key20180107184857_b26-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"Chang","year":"2009","journal-title":"Biochem J"},{"key":"key20180107184857_b27-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180107184857_b28-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20180107184857_b29-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1349-7006.2009.01463.x","article-title":"Antitumor activity of anti-CERC\/mesothelin monoclonal antibody in vivo","volume":"101","author":"Inami","year":"2009","journal-title":"Cancer Sci"},{"key":"key20180107184857_b30-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b31-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab - mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107184857_b32-ijo-41-06-2109","first-page":"129","article-title":"Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver","volume":"30","author":"Huang","year":"2007","journal-title":"Onkologie"},{"key":"key20180107184857_b33-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-6-190","article-title":"Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report","volume":"6","author":"Sprinzl","year":"2006","journal-title":"BMC Cancer"},{"key":"key20180107184857_b34-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clon.2006.03.003","article-title":"Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma","volume":"18","author":"Bralet","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key20180107184857_b35-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b36-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the Chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b37-ijo-41-06-2109","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107184857_b38-ijo-41-06-2109","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2012.1662\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T18:51:49Z","timestamp":1515351109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2012.1662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,10,15]]},"published-print":{"date-parts":[[2012]]}},"alternative-id":["10.3892\/ijo.2012.1662"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2012.1662","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}